Casdin Capital
$2.0B 13F equity value
46 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Casdin Capital covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| RVMD | REVOLUTION MEDICINES INC | 2,577,333 | $483M | 24.2% |
| RLAY | RELAY THERAPEUTICS INC | 16,035,240 | $300M | 15.0% |
| WGS | GENEDX HOLDINGS CORP | 3,707,164 | $254M | 12.7% |
| BLFS | BIOLIFE SOLUTIONS INC | 4,655,000 | $131M | 6.6% |
| ILMN | ILLUMINA INC | 530,000 | $93M | 4.7% |
| LAB | STANDARD BIOTOOLS INC | 88,783,856 | $73M | 3.7% |
| GPCR | STRUCTURE THERAPEUTICS INC | 1,175,000 | $63M | 3.2% |
| DNLI | DENALI THERAPEUTICS INC | 2,045,000 | $53M | 2.6% |
| NGNE | NEUROGENE INC | 1,545,361 | $49M | 2.4% |
| BEAM | BEAM THERAPEUTICS INC | 1,350,000 | $46M | 2.3% |
Track Casdin Capital's 13F portfolio: $2.0B in reported holdings, 46 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}